A carregar...
Future Directions in the Treatment of Osteosarcoma
Osteosarcoma is the most common primary bone sarcoma and is often diagnosed in the 2nd–3rd decades of life. Response to the aggressive and highly toxic neoadjuvant methotrexate-doxorubicin-cisplatin (MAP) chemotherapy schedule is strongly predictive of outcome. Outcomes for patients with osteosarcom...
Na minha lista:
| Publicado no: | Cells |
|---|---|
| Main Authors: | , , , , , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
MDPI
2021
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7829872/ https://ncbi.nlm.nih.gov/pubmed/33467756 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3390/cells10010172 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|